Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

CANbridge Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

CANbridge Pharmaceuticals' CEO'su James Qun Xue, Jan2018 tarihinde atandı, in görev süresi 6.75 yıldır. in toplam yıllık tazminatı CN¥ 9.55M olup, şirket hissesi ve opsiyonları dahil olmak üzere 59.8% maaş ve 40.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 9.85% ine doğrudan sahiptir ve bu hisseler HK$ 15.70M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3 yıl ve 2.7 yıldır.

Anahtar bilgiler

James Qun Xue

İcra Kurulu Başkanı

CN¥9.5m

Toplam tazminat

CEO maaş yüzdesi	59.8%
CEO görev süresi	6.8yrs
CEO sahipliği	9.9%
Yönetim ortalama görev süresi	3yrs
Yönetim Kurulu ortalama görev süresi	2.7yrs

Son yönetim güncellemeleri

Recent updates

CANbridge Pharmaceuticals Inc. (HKG:1228) Stock Catapults 31% Though Its Price And Business Still Lag The Industry

Sep 27

Lacklustre Performance Is Driving CANbridge Pharmaceuticals Inc.'s (HKG:1228) 28% Price Drop

Aug 07

CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 56% But Its Business Prospects Need A Lift Too

Apr 23

CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings

May 05

CEO Tazminat Analizi

James Qun Xue'un ücretlendirmesi CANbridge Pharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CN¥408m
Mar 31 2024	n/a	n/a	-CN¥393m
Dec 31 2023	CN¥10m	CN¥6m	-CN¥379m
Sep 30 2023	n/a	n/a	-CN¥416m
Jun 30 2023	n/a	n/a	-CN¥453m
Mar 31 2023	n/a	n/a	-CN¥468m
Dec 31 2022	CN¥13m	CN¥5m	-CN¥483m
Sep 30 2022	n/a	n/a	-CN¥733m
Jun 30 2022	n/a	n/a	-CN¥982m
Mar 31 2022	n/a	n/a	-CN¥1b
Dec 31 2021	CN¥10m	CN¥4m	-CN¥1b
Sep 30 2021	n/a	n/a	-CN¥1b
Jun 30 2021	n/a	n/a	-CN¥1b
Mar 31 2021	n/a	n/a	-CN¥828m
Dec 31 2020	CN¥6m	CN¥4m	-CN¥846m
Dec 31 2019	CN¥10m	CN¥3m	-CN¥218m

Tazminat ve Piyasa: James Qun 'nin toplam tazminatı ($USD 1.36M ), Hong Kong pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 233.84K ).

Tazminat ve Kazançlar: James Qun 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

James Qun Xue (54 yo)

6.8yrs

Görev süresi

CN¥9,545,000

Tazminat

Dr. James Qun Xue, Ph D., M.B.A., has served as Chairman of the Board and Chief Executive Officer at CANbridge Pharmaceuticals Inc. since January 2018 and as an executive Director on June 21, 2021 and serv...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Qun Xue	Founder	6.8yrs	CN¥9.55m	9.85% CN¥ 18.6m
Glenn Hassan	Chief Financial Officer	5.5yrs	Veri yok	Veri yok
Pauline Li	Senior VP of Clinical Development & Operations	2.4yrs	Veri yok	Veri yok
Qian Ma	Director of Legal & Compliance	3.3yrs	Veri yok	Veri yok
Stella Mao	Senior Director of Public Affairs	4.8yrs	Veri yok	Veri yok
Chris Chen	Vice President of Human Resources	no data	Veri yok	Veri yok
Gerald F. Cox	Chief Development Strategist & Interim Chief Medical Officer	5.3yrs	Veri yok	Veri yok
Wei Zhang	Senior Director & Head of CMC China	less than a year	Veri yok	Veri yok
Rebecca Zhang	Senior Vice President of Regulatory Affairs	2.2yrs	Veri yok	Veri yok
Jeff Kou	Director and Head of Program Management & Clinical Operations	2.8yrs	Veri yok	Veri yok
Fannie Man	Mainland China Commercial Head & GM of Hong Kong and Macau	1.3yrs	Veri yok	Veri yok
Jason West	VP & Head of Gene Therapy Research	no data	Veri yok	Veri yok

3.0yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: 1228 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Qun Xue	Founder	6.8yrs	CN¥9.55m	9.85% CN¥ 18.6m
James Arthur Geraghty	Independent Non-Executive Director	6.3yrs	CN¥317.00k	0.16% CN¥ 311.5k
Peng Kuan Chan	Independent Non-Executive Director	3.3yrs	CN¥317.00k	Veri yok
Edward Hu	Non-Executive Director	2.3yrs	Veri yok	Veri yok
Richard Gregory	Independent Non-Executive Director	4.5yrs	CN¥317.00k	Veri yok
Guangping Gao	Member of Strategic Advisory Board	4.3yrs	Veri yok	Veri yok
Mark A. Goldberg	Member of Strategic Advisory Board	no data	Veri yok	Veri yok
Anthony Amato	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Lan Hu	Independent Non-Executive Director	2.7yrs	CN¥320.00k	Veri yok
Robert Colvin	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Jean Francis	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok
Sushrut Waikar	Member of Scientific Advisory Board	2.3yrs	Veri yok	Veri yok

2.7yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 1228 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.7 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

CANbridge Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

CANbridge Pharmaceuticals Inc. Announces Board and Board Committee Changes

CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee

High number of new and inexperienced directors

CANbridge Pharmaceuticals Inc. Forms Scientific Advisory Board

Canbridge Pharmaceuticals Inc. Announces Board Changes

CANbridge Pharmaceuticals Inc. Appoints Pauline Li as Senior Vice President of Clinical Development and Operations

Recent updates

First half 2024 earnings released: CN¥0.58 loss per share (vs CN¥0.51 loss in 1H 2023)

CANbridge Pharmaceuticals Inc. (HKG:1228) Stock Catapults 31% Though Its Price And Business Still Lag The Industry

CANbridge Pharmaceuticals Inc. Announces Board and Board Committee Changes

CANbridge Pharmaceuticals Inc. to Report First Half, 2024 Results on Aug 29, 2024

Lacklustre Performance Is Driving CANbridge Pharmaceuticals Inc.'s (HKG:1228) 28% Price Drop

Consensus EPS estimates fall by 23%

Price target decreased by 21% to HK$7.00

Consensus EPS estimates upgraded to CN¥0.59 loss

CANbridge Pharmaceuticals Inc.'s (HKG:1228) Share Price Boosted 56% But Its Business Prospects Need A Lift Too

Full year 2023 earnings: EPS and revenues exceed analyst expectations

CANbridge Pharmaceuticals Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee

CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress

CANbridge Announces NDA Acceptance of CAN108 (???®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China's National Medical Products Administration

Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China

Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (Algs)

First half 2023 earnings released: CN¥0.51 loss per share (vs CN¥0.59 loss in 1H 2022)

CANbridge Pharmaceuticals Inc. to Report First Half, 2023 Results on Aug 30, 2023

Price target decreased by 82% to HK$1.70

Consensus revenue estimates decrease by 22%, EPS upgraded

New minor risk - Share price stability

CANbridge Pharmaceuticals Inc. Announces Preliminary Clinical Data of Phase 1B Study of Omoprubart (CAN106) in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Consensus EPS estimates upgraded to CN¥1.05 loss

CANbridge Pharmaceuticals, Inc. Announces Marketing Approval of CAN108 (LIVMARLI) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

CANbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in China Region of the Global LIVMARLI(R) (CAN108) EMBARK Phase 2 Study in Biliary Atresia

CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings

Full year 2022 earnings: EPS and revenues exceed analyst expectations

CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China

High number of new and inexperienced directors

First half 2022 earnings released: CN¥0.59 loss per share (vs CN¥46.79 loss in 1H 2021)

CANbridge Pharmaceuticals Inc. to Report First Half, 2022 Results on Aug 24, 2022

Canbridge Pharmaceuticals Inc. Announces First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2 Trial for the Treatment of Gaucher Disease in China

CANbridge Pharmaceuticals Inc. Announces First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China

CANbridge Pharmaceuticals Inc. Forms Scientific Advisory Board

Canbridge Pharmaceuticals Inc. Announces Board Changes

CANbridge Pharmaceuticals Inc. Announces Results from its CAN106 Phase 1 Trial

CANbridge Pharmaceuticals Inc. Appoints Pauline Li as Senior Vice President of Clinical Development and Operations

High number of new and inexperienced directors

CANbridge Pharmaceuticals Inc. Announces Executive Changes

CANbridge Pharmaceuticals Inc. Announces First Patient Has Been Dosed in the Can106 Phase 1B/2 Trial for Treatment of Paroxysmal Nocturnal Hemoglobinuria in China

Canbridge Pharmaceuticals Inc. Announces Approval of Can108 for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone

CANbridge Pharmaceuticals Inc. Announces Board Changes

CANbridge Pharmaceuticals Inc. Reports Positive Top-Line Can106 Phase 1 Data

CANbridge Pharmaceuticals CAN108 New Drug Application (NDA) for Alagille Syndrome Accepted by China’s National Medical Products Administration

CANbridge Pharmaceuticals Inc. has completed an IPO in the amount of HKD 685.13718 million.

Less than half of directors are independent

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş